

EMESS BIOSCIENCES LIMITED
UNAUDITED
FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2018

RPG CROUCH CHAPMAN LLP
Chartered Accountants
62 Wilson Street
London
EC2A 2BU

THURSDAY



L820JRKJ

LD5

04/04/2019

#19

COMPANIES HOUSE

EMESS BIOSCIENCES LIMITED
REGISTERED NUMBER:06944607

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2018

	Note	2018 £	2017 £
Fixed assets			
Investments	4	7,103,821	2,057,287
Current assets			
Debtors	5	6	6
		<u>6</u>	<u>6</u>
Creditors	6	(184,136)	(183,761)
		<u>(184,130)</u>	<u>(183,755)</u>
Net current liabilities		(184,130)	(183,755)
Total assets less current liabilities		6,919,691	1,873,532
Provisions for liabilities			
Deferred tax	7	(1,391,438)	(382,209)
		<u>(1,391,438)</u>	<u>(382,209)</u>
Net assets		<u>5,528,253</u>	<u>1,491,323</u>
Capital and reserves			
Called up share capital		6	6
Revaluation reserve		5,567,303	1,529,998
Profit and loss account		(39,056)	(38,681)
		<u>5,528,253</u>	<u>1,491,323</u>

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on
M J Sinclair
 Director

The notes on pages 3 to 6 form part of these financial statements.

25.3.19

EMESS BIOSCIENCES LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2018**

	Called up share capital £	Revaluation reserve £	Profit and loss account £	Total equity £
At 1 July 2016	6	630,450	(38,293)	592,163
Comprehensive income for the year				
Profit for the year	-	-	899,160	899,160
Transfer of surplus on revaluation	-	-	(899,548)	(899,548)
Surplus on revaluation of other fixed assets	-	899,548	-	899,548
At 1 July 2017	6	1,529,998	(38,681)	1,491,323
Comprehensive income for the year				
Profit for the year	-	-	4,036,930	4,036,930
Transfer of surplus on revaluation	-	-	(4,037,305)	(4,037,305)
Surplus on revaluation of other fixed assets	-	4,037,305	-	4,037,305
Other comprehensive income for the year	-	4,037,305	(4,037,305)	-
Total comprehensive income for the year	-	4,037,305	(375)	4,036,930
At 30 June 2018	6	5,567,303	(39,056)	5,528,253

The notes on pages 3 to 6 form part of these financial statements.

EMESS BIOSCIENCES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2018

1. General information

The company is a private company limited by shares registered in England. The company's registered office address is The Copper Room, Deva Centre, Trinity Way, Manchester M3 7BG.

The company's principal activity is that of investment in, management of and consultancy for businesses in the biosciences sector.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 Valuation of investments

Investments in listed company shares are remeasured to market value at each Statement of Financial Position date. Gains and losses on remeasurement are recognised in profit or loss for the period.

2.3 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.4 Financial instruments

The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

EMESS BIOSCIENCES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2018

2. Accounting policies (continued)

2.5 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.6 Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Statement of Comprehensive Income in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of Financial Position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.

2.7 Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of Financial Position date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

3. Employees

The average monthly number of employees, including directors, during the year was 2 (2017 - 2).

EMESS BIOSCIENCES LIMITED**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2018****4. Fixed asset investments**

	Listed investments £
Cost or valuation	
At 1 July 2017	2,057,287
Revaluations	5,046,534
At 30 June 2018	<u>7,103,821</u>
Net book value	
At 30 June 2018	<u>7,103,821</u>
At 30 June 2017	<u>2,057,287</u>

5. Debtors

	2018 £	2017 £
Other debtors	<u>6</u>	<u>6</u>

6. Creditors: Amounts falling due within one year

	2018 £	2017 £
Other creditors	182,747	182,372
Accruals and deferred income	1,389	1,389
	<u>184,136</u>	<u>183,761</u>

Included under creditors is a loan of £182,747 (2017: £182,372) owed to a director of the company. The loan is interest free and repayable on demand.

EMESS BIOSCIENCES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2018

7. Deferred taxation

	2018 £
At beginning of year	(382,209)
Charged to profit or loss	(1,009,229)
<u>At end of year</u>	<u>(1,391,438)</u>

The provision for deferred taxation is made up as follows:

	2018 £	2017 £
Accelerated capital allowances	(1,391,438)	(382,209)
	<u>(1,391,438)</u>	<u>(382,209)</u>

8. Share capital

	2018 £	2017 £
<u>Allotted, called up and fully paid</u>		
6 (2017 - 6) Ordinary shares of £1.00 each	6	6
	<u>6</u>	<u>6</u>